U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug…
Regional Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in Missouri through its partnership with Regional Dermatology, LLC. Founded in 2010 by Sarah Jensen, M.D.,…
Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a national leader in strategic program development for cardiovascular services, today…
Atlas Oncology Partners Raises $28M Series A to Scale Value-Based Oncology Care Atlas Oncology Partners today announced the closing of its Series A financing. Atlas was founded by Rubicon Founders, a healthcare investment firm focused on building and growing companies…
NashBio Announces Key Leadership Roles, Advancing Technological Enablement and Access to Real-World Data Nashville Biosciences LLC a leading real-world, multi-omics data company, today announced the appointment of Wacey Richards to Chief Technology Officer (CTO) and Elizabeth Ann Stringer to Chief…
HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Named a 2026 Edison Awards Finalist HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the Women’s…
NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis,…
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to…
Ethris and German Center for Infection Research (DZIF) Announce Strategic Collaboration to Develop mRNA-Based Vaccines Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, DZIF), today announced…
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) Genentech, a member of the Roche Group announced today new late-breaking data from the Phase III FENtrepid study showing…
Roche’s fenebrutinib becomes the first investigational therapy in over a decade to slow disability progression in primary progressive multiple sclerosis (PPMS) Roche announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK)…
Morgan Stanley to Host 17th Annual Go Red Women’s Leadership Event in Collaboration with the American Heart Association In special recognition of the Go Red for Women® campaign, Morgan Stanley Wealth Management will collaborate with the American Heart Association in Westchester…